- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
MedPage Today Survey Finds rosiglitazone (Avandia) Out of Favor for New Patients
Doctors responding to an online MedPage Today survey overwhelmingly rejected the idea of writing new prescriptions for patients with diabetes for rosiglitazone (Avandia).
Doctors responding to an online MedPage Today survey overwhelmingly rejected the idea of writing new prescriptions for patients with diabetes for rosiglitazone (Avandia).
Seventy-two percent of more than 200 respondents voted no to the question of whether they would start patients on rosiglitazone in view of the published report linking the drug to a 43% increase in the relative risk of myocardial infarction among those with diabetes.
The meta-analysis in the New England Journal of Medicine was conducted by Steven Nissen, M.D., of the Cleveland Clinic, and colleagues.
